Pim‐2 is a critical target for treatment of osteoclastogenesis enhanced in myeloma

E-ISSN： 1365-2141|180|4|581-585

ISSN： 0007-1048

Source： BRITISH JOURNAL OF HAEMATOLOGY, Vol.180, Iss.4, 2018-02, pp. : 581-585

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Unique anti‐myeloma activity by thiazolidine‐2,4‐dione compounds with Pim inhibiting activity

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 180, Iss. 2, 2018-01 ,pp. : 246-258

John Wiley & Sons Inc

Access to resources Recommend Favorite

The Value of Ifosfamide in the Treatment of Multiple Myeloma

Oncology Research and Treatment, Vol. 21, Iss. 2, 1998-06 ,pp. : 30-33

Karger

Access to resources Recommend Favorite

Future Directions in Multiple Myeloma Treatment

Acta Haematologica, Vol. 114, Iss. 1, 2005-09 ,pp. : 8-13

Karger

Access to resources Recommend Favorite

The Nrf2-ARE Pathway: A Valuable Therapeutic Target for the Treatment of Neurodegenerative Diseases

Recent Patents on CNS Drug Discovery, Vol. 7, Iss. 3, 2012-01 ,pp. : 218-229

Bentham Science Publishers

Access to resources Recommend Favorite

Treatment of multiple myeloma: An emphasis on new developments

By Kyle Robert Vincent Rajkumar S.

Annals of Medicine, Vol. 38, Iss. 2, 2006-04 ,pp. : 111-115

Informa Healthcare

Access to resources Recommend Favorite